NI007 / Ethris, Neurimmune - LARVOL DELTA

Neurimmune and Ethris sign collaboration agreement to rapidly develop inhaled mRNA-based antibody therapy for the treatment of Covid-19 (PRNewswire) - "Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19....Based on current development plans, the first product candidate is expected to begin clinical testing in the fourth quarter of 2020, pending regulatory approval."

Licensing / partnership • New molecule • New trial